New Dopamine D3 Receptor Drug Candidate Shows Promise for Restless Legs Syndrome

Restless legs syndrome is a common neurological condition causing uncomfortable urges to move the legs, particularly at night, severely disrupting sleep. Current first-line treatments like pramipexole act broadly on dopamine D2-like receptors and carry risks including augmentation — a paradoxical worsening of symptoms over time — and impulse control disorders. Identifying more targeted therapies is a pressing clinical need.

This study, from a multi-institutional team including NIH and UCLA researchers, evaluated two structurally related but functionally distinct dopamine D3 receptor (D3R) ligands — PG01042 and PG01037 — in an iron-deficient rat model that replicates the periodic limb movements and sleep fragmentation seen in human RLS. The researchers also characterized each compound's biochemical signaling profile using BRET assays in cell culture and molecular dynamics simulations.

The behavioral results were striking: PG01042 dose-dependently reduced periodic limb movements and improved sleep quality, while PG01037 dose-dependently worsened motor symptoms with no sleep benefit. Mechanistically, PG01042 behaved as a D3R partial agonist at both G protein activation and beta-arrestin recruitment pathways. PG01037, by contrast, acted as a partial agonist for beta-arrestin but an inverse agonist at G protein activation — a pharmacologically opposite profile. Molecular simulations traced this functional divergence to subtle differences in how chloro substituents are positioned on the compounds' shared chemical scaffold.

A notable finding was that co-expression of dopamine D1 receptors eliminated the partial agonist effects of both compounds at beta-arrestin recruitment, suggesting receptor-receptor interactions may modulate therapeutic efficacy in vivo.

These results propose a new mechanistic framework: selective D3R partial agonism with the specific signaling profile of PG01042 may reduce RLS symptoms without the liabilities of broad dopamine agonism. Clinical translation remains years away, but the work provides a strong preclinical rationale.